The
global Drug Discovery Software market valued at ~$2 billion
in Next five years and is expected to grow at a CAGR of ~14% to cross $3.5
billion by 2025, driven by growing R&D spending across the world,
need for cost-efficiency & faster time-to-market, stringent regulatory
compliance/reporting, growing use of AI & ML in drug discovery, and rising
demand for novel software solutions specifically designed for biologics/cell
& gene therapy.
The life science industry is rapidly evolving and is
increasingly looking for software solutions to research and innovate in the
most efficient and accurate way possible. The drug discovery software market
(such as ligand-based design, structure-based design, LIMS, ELN, etc.) is
driven by the increasing R&D spend and pipeline, expanding scope and scale,
increasing stringency of testing and regulations, growing number and size of
biotechs, need for increasing cost efficiencies and reducing time to market, and
move towards web/cloud-based software.
Download a free sample report now 👉
https://meditechinsights.com/drug-discovery-software-market/request-sample/
Drug Discovery Software Market – Niche but Fast-Growing
Market
The drug discovery software market is niche and growing
rapidly, driven by the rising pressure on the pharma and biotech companies to
cut costs in the research and preclinical stage of drug development, reduce
timelines and improve transparency through deep learning software tools.
“Large players present in this segment are trying to
consolidate the market by becoming a one stop shop. Moreover, companies are
also considering to combine their solutions with bioinformatics and LIMS tools
to have a competitive edge.” - Executive, Leading Drug Discovery
Software Provider, US
Increasing Focus on Developing AI/ML platforms for Drug
Discovery
The life sciences industry is increasingly recognizing the
benefits offered by big data and AI/ML in drug discovery. Big data combined
with AI/ML is facilitating data point generation in incomplete and often noisy
datasets, reducing the need for complex experiments limited by output capacity
or costs. Several AI/ML developments could be seen recently that are expected
to disrupt the current drug discovery landscape. For instance, in Mar 2021,
insitro, a ML-driven drug discovery and development company raised $400 million
in a Series C financing. In 2020, Optibrium launched Cerella, an AI software
platform for drug discovery.
Rising Demand for Software Solutions Specifically
Designed for Biologics
With rapidly expanding research on advanced therapies like
cell and gene therapies and healthy CGT pipeline, there is robust demand for
software solutions to maximize process and workflow efficiencies across
services. Biologics are expected to experience strong growth in the drug
discovery phase. 50% of drugs currently in the preclinical phase are biologics.
To leverage growth opportunities, companies are entering/expanding into
biologics software space.
Transition to Web/Cloud-based Software
With the growing need for data sharing across and between
organizations, traditional on-premise installations face challenge to survive
in a data-driven world. On-premise systems lack scalability and easy
integration, are often time-consuming and costly to implement and manage. The
drug discovery software industry is slowly moving towards web/cloud-based
solutions as it can address most of these issues with quick deployment, minimum
upfront costs, high flexibility and scalability making it affordable for even
small and medium size pharma/biotechs, academic research/universities and CROs.
Download a sample report for in-depth competitive
insights
https://meditechinsights.com/drug-discovery-software-market/request-sample/
Competitive Landscape: Drug Discovery Software market
The global drug discovery software market is highly
competitive and fragmented. Some of the key players include Dassault Systèmes,
LabVantage, PerkinElmer, Schrodinger, Abbott, Healx, Optibrium, Instem,
Chemical Computing Group, dotmatics, idbs, Titian, Biovia, Celsius, Genome
Biologics, Molsoft, Openeye, BullFrog AI, Atomwise, Owkin, Standigm, insitro,
AbCellera, Recursion and CytoReason.
About Medi-Tech
Insights
Medi-Tech Insights is a healthcare-focused business research
& insights firm. Our clients include Fortune 500 companies, blue-chip
investors & hyper-growth start-ups. We have completed 100+ projects in
Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma
Services in the areas of market assessments, due diligence, competitive
intelligence, market sizing and forecasting, pricing analysis &
go-to-market strategy. Our methodology includes rigorous secondary research combined
with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply
side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
Comments
Post a Comment